Biotechnology

Cue BioPharma

Cue BioPharma released FY2026 Q1 earnings on May 14 (EST), actual revenue USD 5.686 M (forecast USD 2.5 M), actual EPS USD -1.08 (forecast USD -3.3)

Cue Biopharma Enters into Exclusive License Agreement with Ascendant Health Sciences

Cue Biopharma Secures Exclusive License for Allergy Drug

Cue BioPharma's stock price declines due to low market expectations

Cue BioPharma released FY2025 annual earnings on March 16 (EST), actual revenue USD 27.47 M (forecast USD 6.5 M), actual EPS USD -8.4244 (forecast USD -12)

Cue BioPharma released FY2025 Q4 earnings on March 16 (EST), actual revenue USD 21.94 M (forecast USD 1 M), actual EPS USD 0.0143 (forecast USD -0.09)

Cue BioPharma released FY2025 Q3 earnings on November 12 (EST), actual revenue USD 2.149M (forecast USD 2.29M), actual EPS USD -0.0738 (forecast USD -0.0933)

Cue BioPharma released FY2025 9 Months Earnings on November 12 (EST), actual revenue USD 5.524 M, actual EPS USD -9.8327

Cue Biopharma Reports Quarterly Earnings Exceeding Expectations With Share Price Increase

Cue BioPharma released FY2025 Semi-Annual Earnings on August 12 (EST), with actual revenue of USD 3.374 M and EPS of USD -7.3319

Cue BioPharma released FY2025 Q2 earnings on August 12 (EST), actual revenue USD 2.954 M (forecast USD 2 M), actual EPS USD -2.6656 (forecast USD -3.9)

Cue Biopharma Provides Latest Clinical Progress on CUE-101

Cue Biopharma's CUE-401 Receives Positive FDA Pre-IND Feedback

Cue Biopharma Inc CEO Serves as Interim CFO

Cue BioPharma released FY2025 Q1 earnings on May 12 (EST), actual revenue USD 421 K (forecast USD 1.268 M), actual EPS USD -4.952 (forecast USD -4.6)

Cue Biopharma Inc Predicts Q1 2025 EPS Loss of 15 Cents

Cue Biopharma Inc Expected to Report EPS Loss of 15 Cents in Q1

Cue Biopharma Announces $20 Million Public Offering

Boehringer Ingelheim and Cue Biopharma Form Strategic Partnership to Develop New Drug

Cue Biopharma Inc Reports Quarterly Financial Results, Analysts Maintain 'Strong Buy' Rating

InMed Pharmaceuticals

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

Amesite

CN Energy

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

NextNRG

Meiwu Tech

Generation Income Properties

MetaVia

OceanPal

Cue Biopharma reported its Q1 2026 financial results, highlighting strategic developments including a $30 million private placement and a $7.5 million milestone payment. The company enhanced its portfolio with CUE-221, targeting allergic diseases, and hosted a virtual R&D day for CUE-401, aimed at autoimmune diseases. Revenue increased to $5.7 million, while net loss decreased to $5.2 million. Shao-Lee Lin was appointed as President and CEO to lead the company's growth and transformation into a clinical-stage entity, with significant milestones expected in the second half of 2026.

StockTitan

ONO Pharmaceutical Co., Ltd.

Ono Pharmaceutical

Cue Biopharma Reports First Quarter 2026 Financial Results and Recent Strategic Developments | CUE Stock News

Cue Biopharma, Inc. (Nasdaq: CUE) announced the grant of inducement equity awards to seven new employees, including CEO Shao-Lee Lin, on May 3, 2026. The awards, approved by independent directors, include stock options and restricted stock units under the 2026 Inducement Stock Incentive Plan, in compliance with Nasdaq Listing Rule 5635(c)(4). Dr. Lin received options for 655,074 shares and fully vested restricted stock units for 327,537 shares. Other new employees received options for 518,599 shares and fully vested units for 327,534 shares. Cue Biopharma focuses on developing therapies for immunological disorders.

Cue Biopharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | CUE Stock News

CRCL

Circle pre-market up 4.97%; Cue BioPharma pre-market down 4.83%; Credit Suisse High Yield Credit Fund pre-market up 244.83%; Skycorp Solar pre-market up 109.42%; Rallybio pre-market up 40.28%

Price Alert

Circle

Credit Suisse High Yield Credit Fund

Skycorp Solar

Rallybio

Pre-market hot trades in US stocks: Circle up 4.97% in pre-market; Cue BioPharma down 4.83% in pre-market

Cue Biopharma Inc. (CUE) shares surged 67.57% to $24.70 after announcing a $30 million private investment, a Phase 2 anti-IgE antibody license, and the appointment of Dr. Shao-Lee Lin as CEO. The PIPE financing will support the development of Ascendant-221, an anti-IgE monoclonal antibody, and general corporate needs. CUE has a market cap of $47.98 million and has seen a 34.92% decline over the past year, but is currently trading near its 52-week high.

fidelity

ACELYRIN

Beyond Meat

Cue Biopharma Stock Surges Over 65% Overnight: Why Is It Moving?

Cue Biopharma（CUE.US）现价 $26.500，当日 +79.78%，盘中涨势显著，市值 0.92 亿。公司专注于免疫药物研发，股价因盘前及盘后持续上涨引发关注。近日媒体报道公司盘前大涨超过 65%，市场聚焦其潜在临床进展和资金流入，催化原因未有明确公告。

Movers Alert

Cue Biopharma (CUE) surges nearly 80% intraday

Cue Biopharma has secured an exclusive license for the anti-IgE asset Ascendant-221 from Ascendant Health Sciences, involving a $15 million upfront payment and potential milestones totaling up to $676.5 million. The agreement includes pre-funded warrants for Ascendant, allowing for a potential 7.5% ownership stake. Additionally, Cue plans to raise approximately $30 million through a private placement of warrants. These transactions aim to expand Cue's pipeline and support its development and corporate needs.

TradingView

Cue Biopharma Licenses Anti-IgE Asset From Ascendant; $15M Upfront, Up to $676.5M in Milestones